Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EDAP TMS S.A. American Depositary Shares (FOCL)
Vaulx-en-Velin, ARA, FR
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.43% | +5.36% | +13.46% | +20.41% | +63.89% | +43.47% | +176.02% | -48.53% | -30.49% | +46.13% | +69.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+2.0% Q1'26: +25.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-41.8% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-37.3% Q1'26: -20.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-40.3% Q1'26: -40.6% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-106.9% Q1'26: -126.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.4% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.11× Q1'26: -1.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
69.35M
est: 68.32M (+1.5%)
|
70.75M
est: 70.76M (0.0%)
|
67.20M
54.92M – 79.48M
-5.0% YoY
|
73.30M
61.25M – 85.35M
+9.1% YoY
|
83.74M
68.38M – 97.30M
+14.2% YoY
|
122.92M
100.37M – 142.81M
+46.8% YoY
|
147.79M
120.68M – 171.71M
+20.2% YoY
|
| EBITDA |
-17.70M
est: -13.55M (-30.6%)
|
-25.05M
est: -14.03M (-78.5%)
|
-13.32M
-15.76M – -10.89M
+5.0% YoY
|
-14.53M
-16.92M – -12.14M
-9.1% YoY
|
-16.60M
-19.29M – -13.56M
-14.2% YoY
|
-24.37M
-28.32M – -19.90M
-46.8% YoY
|
-29.30M
-34.05M – -23.93M
-20.2% YoY
|
| EBIT |
-20.50M
est: -16.20M (-26.6%)
|
-28.47M
est: -16.78M (-69.7%)
|
-15.93M
-18.84M – -13.02M
+5.0% YoY
|
-17.38M
-20.23M – -14.52M
-9.1% YoY
|
-19.85M
-23.07M – -16.21M
-14.2% YoY
|
-29.14M
-33.86M – -23.80M
-46.8% YoY
|
-35.04M
-40.71M – -28.61M
-20.2% YoY
|
| Net Income |
-20.57M
est: -22.62M (+9.0%)
|
-29.34M
est: -25.40M (-15.5%)
|
-33.04M
-39.99M – -25.16M
-30.1% YoY
|
-25.76M
-29.08M – -22.43M
+22.0% YoY
|
-19.71M
-23.85M – -15.01M
+23.5% YoY
|
-3.74M
-4.53M – -2.85M
+81.0% YoY
|
4.49M
3.42M – 5.44M
+220.0% YoY
|
| SGA |
42.58M
est: 36.53M (+16.6%)
|
45.17M
est: 37.84M (+19.4%)
|
35.93M
29.37M – 42.50M
-5.0% YoY
|
39.20M
32.75M – 45.64M
+9.1% YoY
|
44.78M
36.57M – 52.03M
+14.2% YoY
|
65.73M
53.67M – 76.36M
+46.8% YoY
|
79.03M
64.53M – 91.82M
+20.2% YoY
|
| EPS |
-0.55
est: -0.60 (+8.9%)
|
-0.78
est: -0.68 (-15.0%)
|
-0.88
-1.07 – -0.67
-30.1% YoY
|
-0.69
-0.78 – -0.60
+22.0% YoY
|
-0.53
-0.64 – -0.40
+23.5% YoY
|
-0.10
-0.12 – -0.08
+81.0% YoY
|
0.12
0.09 – 0.15
+220.0% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Buy | Buy | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-10 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-09 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ryan Rhodes | CEO & Director | 1M | male |
| Kenneth Mobeck | Chief Financial Officer | 632.6K | male |
| Steven Annen | Executive Vice President of Marketing & Product Management | 418.0K | male |
| Frederic Pech | President of EDAP TMS France | — | male |
| Blandine Confort | Head of Legal Affairs & Investor Relations and Secretary | — | female |
| Sanket Shah | General Counsel & Corporate Secretary | — | male |
| Jean-Francois Bachelard | President & Chief Executive Officer of Edaptechnomed Co. Ltd. | — | male |
| Carre Emmanuel | Chief Operating Officer | — | male |
| Francois Dietsch | Chief Accounting Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FOCL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
